Why this page exists
A research project that only presents positive findings is advocacy, not investigation. The negative evidence, contradictions, and limitations are what make the positive evidence worth trusting.
The AIM-HIGH trial
The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides (AIM-HIGH) trial was a large randomized controlled trial testing niacin added to statin therapy. It was stopped early because niacin showed no additional cardiovascular benefit over statins alone.
AIM-HIGH had a chilling effect on niacin research and clinical use. However, its relevance to niacin's immune effects is limited:
- It tested cardiovascular endpoints, not immune or autoimmune outcomes
- Participants were already on statins, which have their own anti-inflammatory effects
- The dose (1.5-2g/day extended-release) and formulation may matter
- It tells us nothing about GPR109A-mediated immune regulation
The AIM-HIGH result is often cited as evidence that "niacin doesn't work." This is a category error — it showed that niacin doesn't add cardiovascular benefit on top of statins, not that niacin has no biological effects.
Hepatotoxicity
Sustained-release niacin formulations cause hepatotoxicity in a significant fraction of users (52% in one comparative study). This is a real and serious adverse effect — but it is form-specific, not molecule-specific. Immediate-release nicotinic acid showed 0% hepatotoxicity at equivalent doses in the same study.
The mechanism: sustained-release formulations deliver niacin slowly through the portal circulation, overwhelming hepatic first-pass metabolism. Immediate-release creates a brief spike that the liver processes normally.
Missing human evidence
The most significant limitation of the niacin-autoimmune thesis is the lack of human randomized controlled trials specifically designed to test immune outcomes. Most immune evidence comes from:
- Animal models (mouse and rat)
- In vitro studies (cell lines)
- Observational data
- Small case series
- One human colitis study (n=26, no placebo control)
This evidence gap does not invalidate the hypothesis — it means the hypothesis is unproven, not disproven. The mechanistic evidence is strong. The human clinical evidence is thin.
Negative and mixed study results
Not every study shows benefit. Some studies show neutral outcomes for specific conditions at specific doses. These are catalogued in the database and can be filtered via the API.
The pattern in negative results tends to be: wrong form (niacinamide instead of nicotinic acid), insufficient dose, wrong endpoint (cardiovascular rather than immune), or confounded by concurrent therapies.
Methodological limitations across the corpus
- Publication bias: Positive results are published more readily. The true proportion of negative niacin studies is unknown.
- Animal model translation: Mouse and rat immune systems differ from human. The allometric dose scaling is approximate.
- Dose heterogeneity: Studies use widely varying doses, making cross-study comparison difficult.
- Duration: Most studies are short-term. Long-term effects of gram-scale nicotinic acid on immune function are essentially unstudied.
What this means for the reader
The evidence for nicotinic acid's immune effects is mechanistically compelling but clinically incomplete. The receptor mechanism (GPR109A) is well-characterized. The downstream immune effects are documented in models. The translation to human autoimmune treatment is plausible but unproven by rigorous clinical standards.
This is an active investigation, not a settled conclusion.